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In Response:
We would like to thank Troost 
et al. for their interest in our work 
regarding personalizing prescription 
doses using genetic data.1 The authors 
with a favorable profile while seeking 
alternative therapeutic options in the 
remaining patients.
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model a reduction in prescribed dose 
would be necessary in 26 of the 141 
patients studied. All but one of these 
patients belonged to the cohort that 
developed radiation pneumonitis. The 
mean clinically prescribed dose to this 
pneumonitis population was 64.7 Gy as 
opposed to 51.8 Gy predicted to be safe 
by the model. For a subset of the remain-
ing patients, the dose could be slightly 
increased or decreased. This finding is 
intriguing keeping in mind that dose 
escalation in lung radiotherapy is thought 
to substantially increase local tumor con-
trol and ultimately survival.4 Instead of 
decreasing the dose to prevent patients 
from developing unwanted side effects, 
more tailored solutions are feasible. van 
Baardwijk et al.5 successfully pioneered 
an individualized approach escalating 
dose to maximal tolerance while keep-
ing within the normal-tissue constraints, 
both theoretically and clinically. Both 
acute and late toxicity were acceptable. 
Additionally, MAASTRO clinic is cur-
rently conducting a randomized phase II 
trial including 18F-fluorodeoxyglucose-
positron emission tomography informa-
tion for tumor (subvolume) boosting 
(NCT01024829). On the basis of a recent 
in silico study,3 Radboud University 
Nijmegen Medical Centre is carrying 
out the Individualized Dose Escalation 
in Advanced stage non-small cell Lung 
cancer using Volumetric Modulated 
Arc Therapy (IDEAL-VMAT) study 
(NCT01577212), whereby the irradia-
tion dose is increased on an individual 
basis, taking into account multiple 
 normal-tissue constraints.
For patients with both an unfavor-
able genetic profile and dose distribu-
tion, the radiation dose that can be safely 
administered on the basis of the proposed 
model is probably not curative. Therefore, 
the treating radiation oncologist may opt 
for a palliative protocol thereby deceler-
ating tumor progression and alleviating 
tumor-associated complaints while pre-
venting patients from unnecessary treat-
ment-related side effects.
In summary, this article on 
model-based prescription provides new, 
yet prospectively unvalidated, tools 
for individualized dose-prescription in 
non–small-cell lung cancer patients. 
Radiation oncologists are encouraged 
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To the Editor:
With great interest, we read the 
recent publication by Vinogradskiy et 
al.1 The authors apply their radiation 
pneumonitis prediction model combin-
ing dose-volume and genetic compo-
nents (single-nucleotide polymorphisms 
[SNPs]) for isotoxic mean lung dose 
determination. The five SNPs were 
found to predict for radiation pneumoni-
tis and interestingly, they do not directly 
relate to lung injury, but rather to cellular 
repair and the tumor microenvironment.
The authors state that radiation 
pneumonitis is the dominant dose- 
limiting constraint in thoracic radiother-
apy. This may have been the case for the 
cohort studied for 19% of the patients, 
mostly treated with three-dimensional 
conformal radiotherapy developed radi-
ation pneumonitis of grade 3 or higher. 
With the introduction of highly confor-
mal radiotherapy delivery techniques 
and by abandoning elective nodal irra-
diation, acute grade 3 esophagitis is 
increasingly the dose-limiting toxicity 
based both on clinical experience2 and 
in silico studies.3 As opposed to radia-
tion pneumonitis, this burdensome side 
effect is not fatal but gradually develops 
during the course of (chemo)radiother-
apy, lasting for several weeks thereaf-
ter necessitating analgesic medication 
and dietary alterations in the majority 
of patients. Moreover, late esophageal 
sequelae may develop, adversely influ-
encing the patients’ quality of life.
Vinogradskiy et al.1 found that on 
the basis of the isotoxic physico-genetic 
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bring up several salient points that war-
rant further discussion. The first issue 
raised is that with developing technol-
ogy and in certain instances acute grade 
III esophagitis may be the dose-limiting 
factor for thoracic tumors. We agree 
that every clinical case is unique and 
the dose-limiting organ can be depen-
dent on tumor location, tumor size, 
and treatment technique and design. 
However, the risk of radiation pneu-
monitis is still considered by many 
groups to be one of the most critical 
limiting factors in increasing doses to 
lung tumors.2 The aim of our work was 
to illustrate the concept of personaliz-
ing prescription doses, based on avail-
able single nucleotide polymorphism 
and radiation pneumonitis data. We 
believe the idea of personalized toxicity 
estimates can and should be expanded 
to other thoracic organs at risk as data 
become available and model accuracy 
improves.
For some of our simulations we 
noted that our model indicated lower 
tumor doses (implying dose de-esca-
lation) than what was clinically deliv-
ered for a cohort of patients to keep 
the clinical severe pneumonitis at an 
acceptable level. We should underline 
that we are not suggesting the idea of 
dose de-escalation but rather this result 
is a product of our study design. For a 
percentage of our patient cohort, the 
simulation suggested dose de-escala-
tion because at the time of treatment 
the physician made a clinical judg-
ment to exceed constraints that we set 
for the nonlung organs (esophagus, 
spinal cord, and heart). When those 
patients were excluded from the study, 
the changes in prescription dose were 
approximately zero, indicating that the 
positive and negative changes in dose 
cancelled out; which can be expected 
when the same data set is used for gen-
erating the model and performing the 
simulation. With the above in mind, 
our results still show some patients 
for whom the model suggested a dose 
de-escalation to control the incidence 
of pneumonitis. For those patients, we 
completely agree with Troost et al. in 
that tumor control is of primary impor-
tance and “more tailored solutions are 
feasible.” Instead of dose de-escalation 
we cite some examples of redesigning 
the beam arrangement or replanning 
the patient with different treatment 
modalities (protons versus photons 
for example).1 The work done by Van 
Baardwijk et al.3 is also an excellent 
example of how the dose can be esca-
lated while keeping toxicity rates at an 
acceptable level. There are many ways 
to adapt a treatment plan based on a 
patient’s personalized toxicity risk, and 
we feel it is important to characterize 
each step individually before a com-
plete paradigm of treatment personal-
ization is clinically implemented. The 
aim of our work was to characterize 
one step of the process rather than pro-
pose a complete solution.
The virtual trial presented in our 
work is a proof of principle study and 
should be placed in proper perspective. 
The personalized toxicity work is one 
step in a multistep complicated pro-
cess. The model will not replace tumor 
control consideration, the clinical judg-
ment of the physician, or vary patient 
and clinical scenarios. More work will 
be needed to determine how the results 
from personalized toxicity estimates 
can be properly incorporated into the 
treatment process.
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To the Editor:
It is important to correct the 
record concerning the Mesothelioma 
and Radical Surgery (MARS) trial1 
referred to in the November issue of 
the Journal of Thoracic Oncology by 
Hedi Kindler2 and Valerie Rusch et al.3 
The points they raise here have been 
rehearsed at conferences around the 
world in the course of discussion of the 
place of extrapleural pneumonectomy 
(EPP) for malignant pleural mesothe-
lioma. They merit examination and, in 
some instances, robust rebuttal.
MARS reported just 50 random-
ized patients, a small number.1,4 The 
Clinical Trials Awards and Advisory 
Committee (CTAAC) of Cancer 
Research, United Kingdom funded 
a 50-patient study to test feasibil-
ity, aware of the potential difficulty of 
recruiting and randomizing patients. 
At that time the sample size estimated 
to ensure that a randomized study 
would be 80% sure to detect a sur-
vival advantage attributable to EPP 
was 670 patients. This power calcula-
tion was based on the certificated time 
to death of 426 unoperated patients 
surgically diagnosed with malignant 
pleural mesothelioma compared with 
reported survival of patients who had 
EPP as part of completed multimodal-
ity therapy. Had MARS proceeded to 
the larger study, the 50 patients would 
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